hcv vaccine development - virology educationregist2.virology-education.com/2016/ivhem/18_cox.pdf ·...
TRANSCRIPT
![Page 1: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/1.jpg)
HCV Vaccine Development
Andrea L. Cox, MD,PhD
Professor of Medicine and Oncology
Viral Hepatitis Center
![Page 2: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/2.jpg)
Disclosure speaker
interests
Disclosure of speaker interest
No potential conflicts to report
![Page 3: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/3.jpg)
HCV- Do we need a vaccine?
• Acute infection rates are not decreasing
everywhere
![Page 4: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/4.jpg)
Rising Number of New Acute
HCV Cases in PWID in US
Changes in Rates of New HCV Cases Reported by State, 2010-2014
![Page 5: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/5.jpg)
HCV- Do we need a vaccine?
• Therapies dramatically better but…
![Page 6: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/6.jpg)
HCV- Do we need a vaccine?
• Treatment remains expensive and carries
some side effects
![Page 7: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/7.jpg)
HCV- Do we need a vaccine?
• Treatment remains expensive and carries
side effects
• Finding the people who need treatment
remains challenging
![Page 8: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/8.jpg)
Identification of HCV Infected
people is challenging
• Infection usually silent until ESLD present
![Page 9: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/9.jpg)
Identification of HCV Infected
people is challenging
• Infection usually silent until ESLD present
• Knowledge of infection status limited
Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
![Page 10: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/10.jpg)
Identification of HCV Infected
people is challenging
• Infection usually silent until ESLD present
• Knowledge of infection status limited
• Highest risk groups are marginalized
Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
![Page 11: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/11.jpg)
Identification of HCV Infected
people is challenging
• Infection usually silent until ESLD present
• Knowledge of infection status limited
• Highest risk groups are marginalized
– PWID
Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
![Page 12: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/12.jpg)
Antiviral Therapy Might Be Used to Reduce HCV
Prevalence Among Injecting Drug Users
Annually treating 10 HCV
infections per 1000 IDU and
achieve SVR of 62.5%
Martin et al. Journal of Hepatology 2011
![Page 13: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/13.jpg)
Antiviral Therapy Might Be Used to Reduce HCV
Prevalence Among Injecting Drug Users
Annually treating 10 HCV
infections per 1000 IDU and
achieve SVR of 62.5%
Projected to result in a relative
decrease in HCV prevalence over
10 years of 31%, 13%, or 7% for
prevalences of 20%, 40%, or 60%,
respectively
Martin et al. Journal of Hepatology 2011
![Page 14: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/14.jpg)
Identification of HCV Infected
people is challenging
• Infection usually silent until ESLD present
• Knowledge of infection status limited
• Highest risk groups are marginalized
– PWID
– Living in endemic regions of the world
Centers for Disease Control and Prevention MMWR Recomm. Rec. 47 (RR-19), 1-39 (1998), Nature Outlook Hepatitis C vol 474, 7350, S2
![Page 15: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/15.jpg)
![Page 16: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/16.jpg)
HCV- Do we need a vaccine?
Treatment remains expensive and carries side effects
Finding the people who need treatment remains challenging
Drugs do not provide protection against reinfection
![Page 17: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/17.jpg)
HCV- Do we need a vaccine?
Treatment remains expensive and carries side effects
Finding the people who need treatment remains challenging
Drugs do not provide protection against reinfection
PWID
MSM
![Page 18: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/18.jpg)
HCV- Do we need a vaccine?
Treatment remains expensive and carries side effects
Finding the people who need treatment remains challenging
Drugs do not provide protection against reinfection
Potential for DAA resistance unknown
![Page 19: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/19.jpg)
HCV- Do we need a vaccine?
Treatment - expensive and carries side effects
Finding people who need treatment challenging
Drugs do not provide protection against reinfection
Potential for DAA resistance unknown
Persistence of RAV- esp for NS5a
![Page 20: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/20.jpg)
HCV- Do we need a vaccine?
Treatment - expensive and carries side effects
Finding people who need treatment challenging
Drugs do not provide protection against reinfection
Potential for DAA resistance unknown
Persistence of RAV- esp for NS5a
![Page 21: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/21.jpg)
HCV- Do we need a vaccine?
Treatment - expensive and carries side effects
Finding people who need treatment challenging
Drugs do not provide protection against reinfection
Potential for DAA resistance unknown
Persistence of RAV- esp for NS5a
Increase likely with treatment of less compliant patients
![Page 22: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/22.jpg)
HCV- Do we need a vaccine?
Treatment - expensive and carries side effects
Finding people who need treatment challenging
Drugs do not provide protection against reinfection
Potential for DAA resistance unknown
Persistence of RAV- esp for NS5a
Increase likely with treatment of less compliant patients
RAV testing and long treatment courses won’t happen in resource limited settings
![Page 23: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/23.jpg)
HCV- Do we need a vaccine?
Treatment remains expensive and carries side effects
Finding the people who need treatment remains challenging
Drugs do not provide protection against reinfection
Potential for DAA resistance unknown
![Page 24: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/24.jpg)
Reinfection with DAA resistant HCV
Franco et al. Gastroenterology 2014
HIV-infected male sexual partners with HCV:
SVR in one
DAA failure in the other with documented telaprevir
resistant HCV (V36M)
![Page 25: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/25.jpg)
Reinfection with DAA resistant HCV
Franco et al. Gastroenterology 2014
Documented re-infection with
telaprevir resistant HCV (V36M)
![Page 26: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/26.jpg)
HCV- Do we need a vaccine?
Treatment remains expensive and carries side effects
Finding the people who need treatment remains challenging
Drugs do not provide protection against reinfection
Potential for DAA resistance unknown
Treatment in the later stages doesn’t reverse all disease
![Page 27: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/27.jpg)
Eradication of HCV reduces but doesn’t
eliminate liver failure
Van der Meer JAMA 2012; Backus Clin Gastro 2011; Imazeki Hepatology 2003; Shiratori Ann
Intern Med 2005; Veldt et al Ann Intern Med 2007; Berenguer Hepatology 2009;
![Page 28: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/28.jpg)
Incidence of HCC after SVR is high in
cirrhotics.
El-Serag, et. al. Risk of Hepatocellular Carcinoma after SVR in Veterans with
HCV Infection, Hepatology, 2016 Jul;64(1):130-7.
![Page 29: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/29.jpg)
Is protective immunity possible?
![Page 30: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/30.jpg)
Is protective immunity possible?
• Reinfection does not always result in
clearance- no protective immunity
![Page 31: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/31.jpg)
Is protective immunity possible?
• Reinfection does not always result in
clearance- no protective immunity
• Some evidence that says yes…
![Page 32: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/32.jpg)
BBAASH Cohort
Baltimore Before and After Acute Study of Hepatitis
(BBAASH)
Persistent Infection
Spontaneous
Clearance
Anti-HCV Ab = black bar HCV = red bar
18-35yo Active IDU
HCV EIA & RNA neg
![Page 33: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/33.jpg)
Protection from Persistent HCV
p = 0.001 compared to initial infection(P =.001)
Osburn et. al. Gastroenterolgy 2010;138:315–324
![Page 34: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/34.jpg)
1 e + 1
1 e + 2
1 e + 3
1 e + 4
1 e + 5
1 e + 6
1 e + 7
1 e + 8
1 e + 9
Ma
x D
ete
cte
d H
CV
RN
A (
IU/m
l)
P r im a ry
In fe c t io n
S u b s e q u e n t
In fe c t io n s
P < 0 .0 5
Decreased magnitude of viremia
during reinfection
includes persistently reinfected subjectsOsburn et. al. Gastroenterolgy 2010;138:315–324
![Page 35: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/35.jpg)
Evidence of protective immunity
• Peak HCV RNA level significantly lower during
reinfection than primary infection
– Mehta et. al. Lancet 2002,
– Grebely et. al. Hepatology 2006
– Sacks-Davis et. al. JID 2015
![Page 36: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/36.jpg)
Shorter duration of viremia
during reinfection
Osburn et. al. Gastroenterolgy 2010;138:315–324
![Page 37: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/37.jpg)
Broadening of T cell responses in
HCV Reinfection
P < 0.05
Updated from Osburn et. al. Gastroenterology 2010;138:315–324
![Page 38: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/38.jpg)
Broadening of T cell responses
in HCV Reinfection• Confirmed in Montreal Acute Hepatitis C
Injection Drug User Cohort:
– Increased magnitude and breadth
– Higher T cell proliferative capacity
Abdel-Hakeem, M et. al. Gastroenterolgy 2014, 147;870-881
![Page 39: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/39.jpg)
HCV- Can we make an effective
vaccine?• Challenges parallel to HIV
– Highly diverse virus
![Page 40: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/40.jpg)
BCD
E FA
Ghominoids
0.1
7
5
36
11a
1b1c
4
2
0.1
HCV9198 sites
HBV3181 sites
HIV8316 sites
0.1
CKF
DB
G
AE A J
H
Ray SC and Thomas DL. PPID 7th ed, Chapter 154 2009
![Page 41: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/41.jpg)
HCV- Can we make an effective
vaccine?• Challenges parallel to HIV
– Highly diverse virus
– Unsafe to use live attenuated or killed virus
![Page 42: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/42.jpg)
HCV- Can we make an effective
vaccine?• Challenges parallel to HIV
– Highly diverse virus
– Unsafe to use live attenuated or killed virus
– Increasing interest in vaccines that induce
robust T cell responses
![Page 43: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/43.jpg)
HCV- Can we make an effective
vaccine?• Challenges parallel to HIV
– Highly diverse virus
– Unsafe to use live attenuated or killed virus
– Increasing interest in vaccines that induce
robust T cell responses
– Current focus is to use vectors to deliver viral
antigens in a system that induces robust
innate and adaptive immune responses
![Page 44: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/44.jpg)
HCV- Can we make an effective
vaccine?• Challenges parallel to HIV
– Highly diverse virus
– Unsafe to use live attenuated or killed virus
– Increasing interest in vaccines that induce
robust T cell responses
– Current focus is to use vectors to deliver viral
antigens in a system that induces robust
innate and adaptive immune responses
• Preexisting vector immunity limits responses
![Page 45: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/45.jpg)
Rodents
Proteins in adjuvants,
peptides, DNA, VLP, replicating
& non replicating viral
vectors
Macaques
Chimps
Proteins, VLP, DNA,
Viral vectors
Low-risk Humans
Protein, viral
vectors
High-risk Humans
Viral vectors
Efforts to develop a prophylactic
HCV vaccine
Vaccines for Hepatitis C, 25 Years After the Discovery of Hepatitis C, Springer,
2016
![Page 46: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/46.jpg)
Prophylatic vaccines to generate T cell immunity based on viral vectors
• Low seroprevalence chimpanzee and a human derived Adenoviruses – ChAd3
• MVA attenuated strain, non-replicating in mammalian cells
![Page 47: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/47.jpg)
NS4 NS5A B A BNS3NS3
NS3 ProteaseNS5Bmut
AAG
Met
• Vectored HCV antigen: “NSmut”
Prophylatic vaccines to generate T cell immunity based on viral vectors
![Page 48: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/48.jpg)
NS4 NS5A B A BNS3NS3
NS3 ProteaseNS5Bmut
AAG
Met
• Vectored HCV antigen: “NSmut”• NS3-NS5B (NS = 1985 aa)• Several known human CD4 and CD8 T cell epitopes• Most conserved HCV region • Genotype I, subtype 1b
Prophylatic vaccines to generate T cell immunity based on viral vectors
![Page 49: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/49.jpg)
NS4 NS5A B A BNS3NS3
NS3 ProteaseNS5Bmut
AAG
Met
• Vectored HCV antigen: “NSmut”
Aim: induce antiviral immunity with functional characteristicsanalogous to those associated with viral control in naturalinfection – broadly targeted, durable, functional CD4+CD8+ T cellresponse
Prophylatic vaccines to generate T cell immunity based on viral vectors
![Page 50: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/50.jpg)
• AdCh3NSmut prime with MVANSmut boost is a highly
potent inducer of T cell responses.
HCV Vaccine Healthy Volunteer Trial Summary
Swadling L et al., Science Translational Medicine; 5 November 2014;
6:(261)
![Page 51: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/51.jpg)
• AdCh3NSmut prime with MVANSmut boost is a highly
potent inducer of T cell responses.
• All individuals responded to vaccine.
HCV Vaccine Healthy Volunteer Trial Summary
Swadling L et al., Science Translational Medicine; 5 November 2014;
6:(261)
![Page 52: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/52.jpg)
• AdCh3NSmut prime with MVANSmut boost is a highly
potent inducer of T cell responses.
• All individuals responded to vaccine.
• The majority of subjects developed responses against
multiple HCV proteins.
HCV Vaccine Healthy Volunteer Trial Summary
Swadling L et al., Science Translational Medicine; 5 November 2014;
6:(261)
![Page 53: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/53.jpg)
Figure 2c
![Page 54: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/54.jpg)
• AdCh3NSmut prime with MVANSmut boost is a highly
potent inducer of T cell responses.
• All individuals responded to vaccine.
• The majority of subjects developed responses against
multiple HCV proteins.
• Polyfunctional CD4+ and CD8+ T cells are induced.
HCV Vaccine Healthy Volunteer Trial Summary
Swadling L et al., Science Translational Medicine; 5 November 2014;
6:(261)
![Page 55: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/55.jpg)
• AdCh3NSmut prime with MVANSmut boost is a highly
potent inducer of T cell responses.
• All individuals responded to vaccine.
• The majority of subjects developed responses against
multiple HCV proteins.
• Polyfunctional CD4+ and CD8+ T cells are induced.
• T cells responses across genotypes detected.
HCV Vaccine Healthy Volunteer Trial Summary
Swadling L et al., Science Translational Medicine; 5 November 2014;
6:(261)
![Page 56: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/56.jpg)
Figure 2d
![Page 57: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/57.jpg)
• AdCh3NSmut prime with MVANSmut boost is a highly
potent inducer of T cell responses.
• All individuals responded to vaccine.
• The majority of subjects developed responses against
multiple HCV proteins.
• Polyfunctional CD4+ and CD8+ T cells are induced.
• T cells responses across genotypes detected.
• Vaccines safe and well tolerated.
HCV Vaccine Healthy Volunteer Trial Summary
Swadling L et al., Science Translational Medicine; 5 November 2014;
6:(261)
![Page 58: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/58.jpg)
• Design: Double blind, randomized, placebo controlled at JHU, UCSF, UNM
VIP: Vaccine is Prevention
![Page 59: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/59.jpg)
• Design: Double blind, randomized, placebo controlled at JHU, UCSF, UNM
• Population: 18-45 yo active injection drug users at high risk for but not infected with HCV RNA at screening
VIP: Vaccine is Prevention
![Page 60: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/60.jpg)
• Design: Double blind, randomized, placebo controlled at JHU, UCSF, UNM
• Population: 18-45 yo active injection drug users at high risk for but not infected with HCV RNA at screening
• Size: Total N=540
VIP: Vaccine is Prevention
![Page 61: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/61.jpg)
• Design: Double blind, randomized, placebo controlled at JHU, UCSF, UNM
• Population: 18-45 yo active injection drug users at high risk for but not infected with HCV RNA at screening
• Size: Total N=540
• Goal: assessment of safety, induction of HCV specific immune responses, and efficacy in preventing chronic HCV infection
VIP: Vaccine is Prevention
![Page 62: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/62.jpg)
immune response assessed
W = week
VIP Design
AdCh3 MVA
W88W0 W8
•Two injections administered at 0 and 8 weeks:
AdCh3NSmut1 & MVA-NSmut
•Immune responses assessed
VIP Design
![Page 63: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/63.jpg)
immune response assessed
W = week
VIP Design
AdCh3 MVA
W88W0 W8
•Two injections administered at 0 and 8 weeks:
AdCh3NSmut1 & MVA-NSmut
•Immune responses assessed
• HCV RNA tested monthly
VIP Design
![Page 64: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/64.jpg)
Conclusions
• A prophylactic HCV vaccine is needed.
![Page 65: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/65.jpg)
Conclusions
• A prophylactic HCV vaccine is needed.
– Comprehensive strategy
![Page 66: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/66.jpg)
Conclusions
• A prophylactic HCV vaccine is needed.
– Comprehensive strategy
• Prevention, harm reduction
• Diagnosis
• Treatment
![Page 67: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/67.jpg)
Conclusions
• A prophylactic HCV vaccine is needed.
• Protective immunity likely exists in vivo.
![Page 68: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/68.jpg)
Conclusions
• A prophylactic HCV vaccine is needed.
• Protective immunity likely exists in vivo.
• As with HIV, it will not be easy to create a
successful vaccine.
![Page 69: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/69.jpg)
Conclusions
• A prophylactic HCV vaccine is needed.
• Protective immunity likely exists in vivo.
• As with HIV, it will not be easy to create a
successful vaccine.
• A new prophylactic vaccine is in trials for
the first time in at risk subjects- data due
out in 2017
![Page 70: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/70.jpg)
Acknowledgements
William Osburn
Michael Melia
Shaneca Bowden
Donald Brown
David Hudson
Paula Lum
Alice Asher
Ellen Stein
Our Study
Subjects
Kimberly Page
Katherine Wagner
Stefania Capone
Antonella Folgori
Alfredo Nicosia
Elisa Scarselli
Eleanor BarnesPaul KlenermanLeo Swadling
![Page 71: HCV Vaccine Development - Virology Educationregist2.virology-education.com/2016/IVHEM/18_Cox.pdf · replicating viral vectors Macaques Chimps Proteins, VLP, DNA, Viral vectors Low-risk](https://reader030.vdocuments.mx/reader030/viewer/2022011901/5f0687397e708231d4187005/html5/thumbnails/71.jpg)
• Questions?
Thank you!!!